Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients

Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients

The rate of complete remission (CR) with the anti-PD1 immune checkpoint inhibitors (ICI) nivolumab (N) and pembrolizumab (P) in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) is low (20-30%), and the majority of patients eventually relapse. One strategy to improve their out...

Full description

Bibliographic Details
Main Authors: Elisa Lucchini, Chiara Rusconi, Mario Levis, Francesca Ricci, Armando Santoro, Umberto Ricardi, Stefano Volpetti, Fabio Matrone, Anna Di Russo, Manuela Caizzi, Anna Schiattarella, Francesco Zaja
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Hematology Reports
Subjects:
Nivolumab; pembrolizumab; radiotherapy; Hodgkin lymphoma; ICI-RT
Online Access:https://www.pagepress.org/journals/index.php/hr/article/view/9080

Internet

https://www.pagepress.org/journals/index.php/hr/article/view/9080

Similar Items